IMR Press / EJGO / Volume 26 / Issue 1 / pii/2005107

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Evaluation of soluble tumour necrosis factor alpha receptors p55 and p75 in ovarian cancer patients

Show Less
1 Department of Mother's and Childrens Health,Karol-Marcinkowski University of Medical Sciences, Poznan, Poland
2 Department of Educational Mediczne Karol-Marcinkowski University of Medical Sciences, Poznan, Poland
Eur. J. Gynaecol. Oncol. 2005, 26(1), 43–46;
Published: 10 February 2005

Purpose: Evaluation of serum TNFα receptor 1 (p55) and 2 (p75) concentrations preoperatively in patients with ovarian masses Methods: Estimation by ELISA assay in 51 women with ovarian cancer and 16 healthy controls. Mean values and correlations with CA-125, tumour volume index, morphological score, pathological finding and cytoreduction were estimated Results: Mean concentrations of p55 and p75 in cancer patients were 2006 ± 1030 pg/ml and 2849 ± 1092 pg/ml, respectively, whereby for controls 1323 ± 291 pg/ml and 2386 ± 475 pg/ml, respectively. The area under the ROC curve for CA-125, p55 and p75 for cancer (FIGO Stages I-IV) were: 0.85 (95% CI 0.75-0.92), 0.73 (95% CI 0.60-0.83) and 0.65 (95% CI 0.50-0.77), respec­tively. Serum p55 correlated with morphological ultrasound score and CA-125 but not with FIGO stage, tumour grade or tumour volume index. No correlations of p75 with these parameters were observed. Conclusion: Estimation of p55 and p75 provide little information in ovarian cancer patients and have poor detecting power.

Receptor I
Receptor 2
Tumour marker
Back to top